ESOP expenses deductible as revenue expenditure; investment in subsidiary partly disallowed under Rule 8D.

The Tribunal allowed the assessee's appeal, permitting the deduction of deferred compensation expenses related to ESOP as revenue expenditure. Regarding the Revenue's appeal, the Tribunal partly allowed it, including the investment in the subsidiary for disallowance computation under Rule 8D(2)(iii) but not under Rule 8D(2)(ii).

---

---

Issues Involved:
1. Deferred compensation expenses on account of ESOP.
2. Exclusion of investment in subsidiary for disallowance computation under Section 14A read with Rule 8D.

Issue-wise Detailed Analysis:

1. Deferred Compensation Expenses on Account of ESOP:

The assessee company contested the disallowance of Rs. 5,99,74,467/- as deferred compensation expenses under ESOP, arguing these were incurred in the normal course of business and should be allowed as revenue expenditure. The AO disallowed the expenses, deeming them capital in nature, citing Circular No. 9 of 2007 and the decision in Ranbaxy Laboratories Ltd. v. ACIT, stating that ESOP-related expenses do not constitute actual expenditure but rather a short receipt of share premium.

Upon appeal, the CIT(A) upheld the AO's decision, rejecting the assessee's reliance on the ITAT Chennai decision in SSI Ltd. v. DCIT and other cases, maintaining that ESOP expenses are not business expenditures but merely lesser receipts of share premium.

The Tribunal examined the issue, referring to the Special Bench decision in Biocon Ltd. v. DCIT, which held that ESOP discounts are in the nature of employee costs and deductible during the vesting period. The Tribunal agreed with this view, stating that the expenses are incurred wholly and exclusively for business purposes and should be allowed as business deductions. It emphasized that any unvested or lapsed options should be reversed, and adjustments should be made at the time of exercise of options based on the market price differences.

Thus, the Tribunal allowed the appeal of the assessee, permitting the deduction of Rs. 5,99,74,467/- as deferred employee compensation expenses (ESOP) under the head 'profit and gains of business or profession'.

2. Exclusion of Investment in Subsidiary for Disallowance Computation Under Section 14A Read with Rule 8D:

The Revenue challenged the CIT(A)'s decision to exclude Rs. 4,61,37,00,000/- invested in the subsidiary, India Infoline Investment Services Ltd., from the average value of investments for disallowance computation under Section 14A read with Rule 8D.

The AO had noted that the assessee received dividend income of Rs. 4,78,44,562/- and had substantial investments, but did not attribute any expenses to earning this exempt income. The AO disallowed Rs. 9,20,55,758/- under Rule 8D, which included interest and administrative expenses.

The CIT(A) reduced the disallowance, excluding investments in debentures and foreign subsidiaries that yielded taxable income, and strategic investments in subsidiaries on which no dividend was received. The CIT(A) restricted the disallowance to Rs. 39,427,835/-.

The Tribunal considered the rival submissions and material on record, noting that the investment in the subsidiary was made from the proceeds of fresh shares issued, not borrowed funds. It upheld the CIT(A)'s exclusion of this investment for disallowance under Rule 8D(2)(ii). However, it disagreed with the exclusion for Rule 8D(2)(iii), citing the complexity and strategic nature of such investments, which require substantial management and administrative efforts.

Thus, the Tribunal partly allowed the Revenue's appeal, including the investment in the subsidiary for disallowance computation under Rule 8D(2)(iii) but upheld the CIT(A)'s exclusion under Rule 8D(2)(ii).

Conclusion:

The appeal of the assessee was allowed, permitting the deduction of ESOP expenses as revenue expenditure. The Revenue's appeal was partly allowed, including the investment in the subsidiary for disallowance computation under Rule 8D(2)(iii) but not under Rule 8D(2)(ii).

---